that is essential for AR transactivation, we evaluate the ability of EPI to overcome several clinically relevant AR-related mechanisms of resistance.
for the clinical management of CRPC. EPI is the first inhibitor that binds to the NTD of any steroid hormone receptor to be tested in clinical trials and is initially aimed at CRPC patients that have failed abiraterone or enzalutamide (ClinicalTrials.gov Identifier: NCT02606123).
Conclusion:
These findings support EPI as a promising therapeutic agent to treat CRPC, particularly against tumors driven by constitutively active AR splice variants that are resistant to LBD-targeting drugs.
INTRODUCTION
Most prostate cancers require androgen receptor (AR) transcriptional activity for survival and growth, and therefore, inhibiting androgen synthesis and AR transcriptional activity are the therapeutic approaches to treat advanced prostate cancer. These hormone therapies consist of androgen deprivation therapy (ADT) and application of antiandrogens. Unfortunately, within 12-33 months most patients treated with hormone therapies relapse with a more aggressive and lethal form of the disease referred to as metastatic castration-resistant prostate cancer (mCRPC) (1) . mCRPC is associated with poor prognosis and a mean survival time of 18-36 months (2).
Despite ADT achieving castrate levels of serum testosterone, CRPC is associated with aberrantly restored AR transcriptional activity. The clinical onset of CRPC is characterized by a rise in serum levels of prostate-specific antigen (PSA), which is a gene regulated by AR. There are several possible mechanisms underlying continued transactivation of AR, including amplification of AR (3), gain-of-function mutations within the ligand binding domain (LBD) of AR that enables activation by nonandrogenic steroids or antiandrogens (4, 5) , ligand-independent activation of the AR N-terminus domain (NTD) (6-9), overexpression of AR coactivators (10) (11) (12) (13) (14) , intratumoral de novo synthesis of androgens (15) , and expression of constitutively active AR splice variants with truncated LBD (16, 17) . AR mechanisms of resistance to abiraterone and enzalutamide also include expression of constitutively active AR splice variants, elevated intratumoral androgen, and AR LBD gain-of-function point mutations (18, 19) . Thus novel approaches beyond AR LBD inhibition are required to block AR transcriptional activity for the treatment of mCRPC. One such approach involves targeting AR NTD which would theoretically block all of the above AR mechanisms of resistance.
Activation function-1 (AF-1) in AR NTD is essential for AR transcriptional activity (20) and thus a viable therapeutic target for CRPC. An antagonist of AR AF-1, EPI-002 (2R, 20S) is a single stereoisomer of the EPI-001 mixture (21) . EPI-001, its stereoisomers and analogues (referred to herein as EPI) all effectively inhibit the growth of CRPC xenografts in mice (21, 22) .
Specificity and the mechanism of action of EPI has been elucidated; it specifically binds to Tau5 of AR AF1 to block essential protein-protein interactions required for transcriptional activity of AR (21) (22) (23) (24) . Although at unusually high concentrations of up to 33 times its IC 50 and at a nonphysiological pH of 9.4, EPI can have artifactual off-target effects (25) . Here, we provide evidence that EPI can effectively inhibit aberrant AR transcriptional activity by mechanisms suggested to drive mCRPC such as overexpression of coactivators, AR gain-of-function mutations, and constitutively active AR splice variant. First-in-Human Phase 1/2 clinical trials with EPI-506 (prodrug of EPI-002) are ongoing in Canada and US (ClinicalTrials.gov Identifier: NCT02606123).
MATERIALS AND METHODS

Cell lines, transfection, and proliferation assay
LNCaP cells were from Dr. Leland Chung (Cedars-Sinai Medical Center, Los Angeles, CA).
LNCaP95 cells were from Dr. Stephen R. Plymate (University of Washington, Seattle, WA).
COS-1 cells were from Dr. Rob Kay (Terry Fox Laboratory, Vancouver, BC). LNCaP and COS-1 cells were not further authenticated in our laboratory, but were regularly tested to ensure mycoplasma-free (Venor TM GeM Mycoplasma Detection Kit, Sigma-Aldrich, St. Louis, MO). In September 2013, LNCaP95 cells were authenticated by short tandem repeat analysis and tested to ensure mycoplasma-free at DDC Medical (Fairfield, OH). All cells used were passaged less than 3 months after resuscitation. Transfection for luciferase reporter assays and cell proliferation assay were previously described (22) . Details of transfection, proliferation assay, and plasmids and reagents are in the Supplementary Materials and Methods.
Western blot analysis
SRC-1, SRC-2 (TIF2), and SRC-3 (AIB-1) were probed with purified mouse anti-SRC-1, anti-TIF2, and anti-AIB-1, respectively (BD Biosciences, Franklin Lakes, NJ). p300 was probed using p300 antibody (C-20) (Santa Cruz Biotechnology, Dallas, TX). AR was probed by antiandrogen receptor antibody N-20 (Santa Cruz Biotechnology). Membranes were probed for β-actin using monoclonal mouse anti-β-actin antibody (ab8226 from Abcam, Cambridge, MA).
Protein-protein interaction studies
Cell-free SRC1-3 and AR interactions were analyzed on a Scintistrip microtitre 96-well plate Primers have been described (22, 27) . 
Xenografts and animal study approval
Steroid levels in xenografts and immunohistochemistry
Tumors were removed and 30-50 mg flash frozen for intratumoral steroid measurements as reported (18) and in the Supplementary Materials and Methods.
Statistics
Comparisons between two groups were performed with unpaired 2-tailed Student's t test, and comparisons between three or more groups were performed using One-way or Two-way ANOVA (GraphPad Software, V6). A p value less than 0.05 was considered statistically significant.
RESULTS
EPI maintains effective inhibition of AR transcriptional activity despite elevated levels of coactivators
Elevated levels of AR coactivators such as the p160 steroid receptor coactivator (SRC) family proteins (SRC-1, SRC-2, and SRC-3) and CBP/p300 are associated with prostate cancer progression and poor prognosis (10) (11) (12) (13) (14) . SRC and CBP/p300 directly interact with AR NTD (8, 26, 28, 29) . EPI blocks interaction of AR with CBP (22), but it is unknown if EPI also blocks interaction of AR with SRC. To test this, two approaches were employed. The first approach measured interaction in a cell-free assay with recombinant AR AF1 and SRC1,2,3-CTD proteins.
This approach showed that EPI does not inhibit interaction between AF-1 and any of the SRC family members ( Figure 1A ). The second approach was to immunoprecipitate endogenous protein complexes from LNCaP cells with and without EPI treatment. These studies also showed no effect of EPI on this interaction ( Figure 1B Similarly, overexpression of p300 led to a dose-dependent increase of androgen-induced AR transcriptional activity in LNCaP cells ( Figure 1D , left panel). Western blot analysis confirmed increased expression of p300 when compared to endogenous levels ( Figure 1D right panel) . Both EPI and enzalutamide effectively inhibited AR transcriptional activity in spite of elevated levels of p300 (Figure 1 D, middle panel) .
Inhibition of AR transcriptional activity by EPI is not affected by polymorphic lengths of polyglutamine tract
The human AR gene contains a polymorphic CAG triplet repeat within exon 1 that encodes for a polyglutamine tract in its NTD . The number of CAG repeats ranges between 6-36 in the human population (30) . Since EPI binds AF-1 in the NTD, we tested whether variable lengths of polyglutamine tract would affect the efficacy of EPI to inhibit AR transcriptional activity. AR- Figure   2C ). Western blot analysis revealed that levels of ectopic AR expressed in COS-1 cells were within physiological levels comparable with the endogenous AR level in LNCaP cells ( Figure   2D ). However, expression of AR with 49 repeats of glutamine (CAG49) was reduced compared to the other ARs with shorter tracts. Enzalutamide reduced the total protein levels of AR consistent with previous reports (31) . These results support that variable lengths of polyglutamine tract within the NTD did not diminish inhibition of AR transcriptional activity by EPI.
EPI inhibits transcriptional activities of AR with clinically relevant mutations
To assess the effectiveness of EPI against the transcriptional activities of several clinically relevant AR gain-of-function mutations including mutations found in both the NTD and LBD, we performed AR-driven reporter gene assays using AR-negative COS-1 cells transiently cotransfected with various AR mutants and treated the cells with different inhibitors. First, we examined two AR NTD gain-of-function mutations derived from patients treated with antiandrogens. AR E255K interacts with an E3 ubiquitin ligase and enhances protein stability and androgen-independent nuclear localization (32) . AR W435L increases interaction between the AR NTD and LBD (32) . EPI significantly inhibited androgen-dependent transcriptional activities of these two AR NTD mutations, and the level of inhibition achieved was similar to that of the wild-type (WT) AR ( Figure 3A ). This suggests that these NTD gain-of-function mutations did not impair the effectiveness of EPI to block transcriptional activity of AR. Next, we tested several AR LBD gain-of-function mutations. In the absence of androgen, EPI had no agonist activity which was contrary to hydroxyflutamide and bicalutamide that stimulated substantial AR transcriptional activities for WT AR and the mutants tested ( Figure 3A ).
Enzalutamide also did not stimulate AR activity in the absence of androgen with any of these mutants. In the presence of androgen, EPI significantly blocked the transcriptional activities of WT, V715M, R761G, H874Y, and T877A ( Figure 3A) . Hydroxyflutamide failed to significantly block androgen-dependent transcriptional activities of AR H874Y and T877A, which is consistent with previous reports that these two mutants confer resistance to flutamide (4, 33) . No statistical significance was measured for the percentage of inhibition of androgen-dependent AR transcriptional activities between enzalutamide and EPI, with the exception of WT AR and AR T877A, in which enzalutamide displayed stronger inhibition ( Figure 3B ). Relative levels of ectopic expression of each of the AR mutants are shown in Figure 3C .
EPI blocks the non-canonical transcriptional program regulated by constitutively active AR splice variant
Expression of LBD-truncated and constitutively active AR splice variants AR-V7 or AR-V567es is associated with poor prognosis (17, 34) . EPI inhibits the activities of AR-V567es in the presence and absence of full-length AR while antiandrogens, including enzalutamide, have no effect (21) . AR-V7 is reported to regulate a distinct transcriptional program compared to full- Figure 4B ). Both enzalutamide and EPI decreased androgen-induced levels of PSA and FKBP5 transcript ( Figure   4B ). Next we measured levels of mRNA of genes that are distinctively regulated by AR-V7 such as UBE2C, CDC20, and AKT1 (35) . Firstly, expression of these genes was not induced by androgens thereby supporting that they were not regulated by full-length AR. Consistent with this interpretation, enzalutamide which blocks full-length AR, had no effect on the levels of expression of these genes ( Figure 4C ). Contrary to antiandrogens, EPI significantly reduced the levels of expression of UBE2C, CDC20, and AKT1 ( Figure 4C ). Levels of mRNA for full-length AR and AR-V7 were not significantly affected by enzalutamide or EPI ( Figure 4D ). Nor were protein levels of full-length AR or AR-V7 decreased by any of the treatments compared to relevant controls and androgen treatments ( Figure 4E ). These data support the ability of EPI to inhibit the transcriptional activities of full-length AR and constitutively active AR-V7 to block expression of their target genes.
EPI attenuates the growth of enzalutamide-resistant LNCaP95 xenografts
Proliferation of LNCaP95 cells is androgen-independent and driven by AR-V7 transcriptional activity (16, 35) . Therefore if EPI blocks the transcriptional activity of AR-V7 as suggested here then EPI should also impact the proliferation of these cells. Consistent with previous reports, proliferation of LNCaP95 cells was androgen-independent and resistant to antiandrogens such as bicalutamide and enzalutamide ( Figure 5A ).
Consistent with EPI blocking AR-V7 transcriptional activity, EPI significantly reduced the number of proliferating LNCaP95 cells.
Together these data suggest LNCaP95 cells are enzalutamide-resistant yet sensitive to EPI by a mechanism involving inhibition of the transcriptional activity of AR-V7. To test in vivo effects of EPI on potentially enzalutamide-resistant tumors, LNCaP95 cells were grown as xenografts in male SCID mice that were castrated prior to treatments. EPI significantly attenuated the growth of LNCaP95 xenografts, whereas enzalutamide had no significant effect ( Figure 5B ). By the end of the study, animals treated with EPI had xenografts that were significantly smaller than those treated with vehicle or enzalutamide. EPI reduced the tumor size by more than 50% compared to vehicle control ( Figure 5C, D) , but did not result in tumor regression of LNCaP95 xenografts contrary to regression achieved with EPI in LNCaP xenografts (21, 22) . These studies Figure S1 ). In contrast, enzalutamide had no effect on the proliferation and apoptosis in these xenografts. In accordance with previously published data that enzalutamide increases AR-V7 protein expression in LNCaP95 cells (35), we observed stronger nuclear AR-V7 staining with enzalutamide treatment, while full-length AR staining was similar between the treatment groups ( Figure S2 ). Together these data support the efficacy of EPI in blocking the growth of castration-resistant and enzalutamide-resistant tumors by a mechanism that is consistent with blocking the transcriptional activities of both full-length AR and constitutively active AR splice variants.
DISCUSSION
Restoration of AR transcriptional activity is believed to be the major driver of most lethal mCRPC (39) . Discovery of new drugs that block persistent AR transcriptional activities is crucial for improving the clinical management of this disease. In contrast to all current hormone therapies that act through AR C-terminal LBD, including abiraterone and enzalutamide, an antagonist of AR AF-1 in the NTD has the potential to block all known AR mechanisms of resistance. The present study revealed that EPI, an AF-1 antagonist, was capable of blocking such AR mechanisms of resistance. AR belongs to the steroid hormone receptor family that includes glucocorticoid receptor, progesterone receptor, estrogen receptor and mineralocorticoid receptor. These receptors share structural features such as LBD, DNA-binding domain, and an intrinsically disordered NTD. There are no small molecules reported that bind to NTDs of any other steroid hormone receptor. Thus EPI is precedent in the field of steroid hormone receptors as the first small molecule discovered that directly interacts with AR NTD (21, 22) . AR transcriptional activity is dependent on a functional AF-1 region within its NTD which is comprised of Tau-1 (amino acid residues 110-370) and Tau-5 (amino acid residues 360-528).
Tau-1 and Tau-5 may act independently of one another (20) . EPI binds AF-1 (21, 22) and recent NMR spectroscopy has mapped its binding specifically to .
AR interacts with p160 SRC coactivators through both its C-terminal LBD and AF-1 (40-42) and with CBP/p300 in its NTD (29) . CBP/p300 are bridging factors that are necessary for AR transcriptional activity (29, 43) . The expression levels of SRCs and CBP/p300 are increased in CRPC and these increases in expression are proposed as an AR mechanism of resistance to current hormone therapies (10) (11) (12) (13) (14) . Here, we demonstrated the ability of EPI to maintain an effective and consistent inhibition of AR transcriptional activity in spite of elevated levels of these AR coactivators. EPI did not block interaction of AF-1 with p160 SRCs using recombinant peptides or with endogenous proteins coimmunoprecipitated from cells. This implies that p160
SRCs interaction with AF-1 cannot over-ride or compensate for the loss of interaction with CBP and RAP74 caused by EPI to decrease AR transcriptional activity (22) . P300 and RAP74 interact with Tau-5 of AR AF-1 (24, 44) . RAP74 is a subunit of transcriptional factor IIF (TFIIF) and an essential part of the basal transcriptional machinery to recruit RNA polymerase II that is necessary for transcription. Hence SRC interaction is not sufficient on its own to drive AR transcriptional activity in the absence of RAP74 and CBP/p300.
The length of polyglutamine tract influences interaction of AR with corepressors and AR transcriptional activity (45) . The AR repressor, silencing mediator for retinoic acid and thyroid hormone receptor (SMRT), binds Tau-5 and LBD, and its ability to repress AR activity is highly are correlated with poor prognosis (34) . Aberrant and persistent AR transcriptional activity caused by constitutively active AR splice variants is likely a main common mechanism of resistance to abiraterone and enzalutamide, and compelling evidence suggests that these variants provide resistance to current LBD-targeting therapies in vitro and in vivo (18, 38, 48) . A recent clinical study revealed that the levels of AR-V7 in the circulating tumor cells from CRPC patients are correlated with resistance to abiraterone and enzalutamide (49) . These findings indicate the potential of constitutively active AR variants to be a major mechanism of resistance to current AR LBD-targeting therapies, but more importantly, they highlight the need for inhibitors of AR AF-1. In LNCaP95 cells, that endogenously express both functional full-length AR and AR-V7, EPI reduced the expression of genes regulated by full-length AR such as PSA and FKBP5 and most importantly genes distinctly regulated by AR-V7, such as UBE2C, and CDC20, while enzalutamide had no effect. Androgen-independent proliferation of LNCaP95 cells was significantly reduced by EPI, while antiandrogens had no effect. Consistent with these One-way ANOVA compared the treatment groups to vehicle-R1881 control in (A) , and ARs with variable length of polyglutamine tract in (C); *p < 0.05; **p < 0.01; ***p < 0.001. 
